Wockhardt tanks 7% on
FDA’s warning letter to US arm
Morton Grove
Pharmaceuticals, a subsidiary of the firm, received a
warning letter from the US drug regulator. The move is a blow to the
company as it struggles with regulatory non-compliance.
Wockhardt
tanked nearly 7 percent intraday on Thursday as investors turned
bearish after the company’s US arm received a warning letter from the US
drug regulator.
The US Food and Drug Administration issued a warning letter to Morton
Grove Pharmaceuticals, a stepdown subsidiary of the company in Illinois,
US. “This would mean that current portfolio of the company will
continue to be made available in the market. However, new approvals will
be withheld till resolution,” it told the exchanges in a notification
on Wednesday.